帕博西利联合Taselisib及氟维司群治疗PIK3CA突变乳腺癌的Ib期研究
这项Ib期试验评估了CDK4/6抑制剂帕博西利联合选择性PI3K抑制剂Taselisib双药方案在晚期实体瘤中的安全性及疗效,以及三药方案联合氟维司群在25例PIK3CA突变、ER阳性HER2阴性晚期乳腺癌患者中的疗效。三药方案在该人群的缓解率为37.5%(95%CI 18.8-59.4),双药方案在PIK3CA突变ER阴性乳腺癌及其他实体瘤中观察到持久疾病控制,两种联合方案在药效学活性剂量下耐受良好。
要点
- 三药方案在经治PIK3CA突变ER阳性HER2阴性晚期乳腺癌中缓解率达37.5%。
- 基线cyclin E1高表达及治疗中ctDNA高丰度与更短PFS相关。
- 双药方案在PIK3CA突变三阴性乳腺癌中显示临床获益潜力。
核心结论
- 帕博西利、Taselisib和氟维司群三药方案在经治PIK3CA突变ER阳性HER2阴性晚期乳腺癌中显示有前景的疗效。
研究设计与样本
- Ib期试验,三药方案组纳入25例PIK3CA突变、ER阳性HER2阴性晚期乳腺癌患者。
- 双药方案组评估帕博西利联合Taselisib在晚期实体瘤中的安全性和疗效。
主要发现
- 三药方案在PIK3CA突变ER阳性HER2阴性乳腺癌的缓解率为37.5%(95%CI 18.8-59.4)。
- 双药方案在PIK3CA突变ER阴性乳腺癌及其他实体瘤中观察到持久疾病控制。
- 三药组基线cyclin E1高表达与更短PFS相关(HR=4.2;95%CI 1.3-13.1;P=0.02)。
- 治疗中ctDNA高丰度与更短PFS相关(HR=5.2;95%CI 1.4-19.4;P=0.04)。
- 纵向血浆ctDNA测序提供了三药治疗期间的基因组进化证据。
临床怎么用
- 三药方案可作为经治PIK3CA突变ER阳性HER2阴性晚期乳腺癌的潜在靶向治疗选择。
- 基线cyclin E1高表达或早期ctDNA高丰度提示PFS较短,需密切监测。
- 双药方案可能为PIK3CA突变三阴性乳腺癌提供非化疗靶向治疗途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in PIK3CA-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet CDK4/6 inhibitor palbociclib plus selective PI3K inhibitor taselisib in advanced solid tumors, and triplet palbociclib plus taselisib plus fulvestrant in 25 patients with PIK3CA-mutant, ER-positive HER2-negative advanced breast cancer. The triplet therapy response rate in PIK3CA-mutant, ER-positive HER2-negative cancer was 37.5% [95% confidence interval (CI), 18.8-59.4]. Durable disease control was observed in PIK3CA-mutant ER-negative breast cancer and other solid tumors with doublet therapy. Both combinations were well tolerated at pharmacodynamically active doses. In the triplet group, high baseline cyclin E1 expression associated with shorter progression-free survival (PFS; HR = 4.2; 95% CI, 1.3-13.1; P = 0.02). Early circulating tumor DNA (ctDNA) dynamics demonstrated high on-treatment ctDNA association with shorter PFS (HR = 5.2; 95% CI, 1.4-19.4; P = 0.04). Longitudinal plasma ctDNA sequencing provided genomic evolution evidence during triplet therapy. SIGNIFICANCE: The triplet of palbociclib, taselisib, and fulvestrant has promising efficacy in patients with heavily pretreated PIK3CA-mutant ER-positive HER2-negative advanced breast cancer. A subset of patients with PIK3CA-mutant triple-negative breast cancer derived clinical benefit from palbociclib and taselisib doublet, suggesting a potential nonchemotherapy targeted approach for this population.This article is highlighted in the In This Issue feature, p. 1.
引用
- Pascual J, Lim JSJ, Macpherson IR, et al. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discov. 2020. PMID: 32958578. doi:10.1158/2159-8290.CD-20-0553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。